DWP 216262
Alternative Names: DWP-216262Latest Information Update: 28 Mar 2025
At a glance
- Originator Daewoong Pharmaceutical
- Class Antineoplastics
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mesothelioma; Non-small cell lung cancer
Most Recent Events
- 17 Mar 2025 Preclinical trials in Mesothelioma in South Korea (Parenteral) (Daewoong Pharmaceuticals pipeline, March 2025)
- 17 Mar 2025 Preclinical trials in Non-small cell lung cancer in South Korea (Parenteral) (Daewoong Pharmaceuticals pipeline, March 2025)
- 17 Mar 2025 Daewwong Pharmaceuticals plans to file an IND application in 2025